Experience with the wearable cardioverter-defibrillator in older patients: Results from the Prospective Registry of Patients Using the Wearable Cardioverter-Defibrillator

被引:12
|
作者
Daimee, Usama A. [1 ]
Vermilye, Katherine [1 ]
Moss, Arthur J. [1 ]
Goldenberg, Ilan [1 ]
Klein, Helmut U. [1 ]
McNitt, Scott [1 ]
Zareba, Wojciech [1 ]
Kutyifa, Valentina [1 ]
机构
[1] Univ Rochester, Med Ctr, Div Cardiol, Heart Res Follow Up Program, 265 Crittenden Blvd,Box 653, Rochester, NY 14642 USA
关键词
Compliance; Implantable cardioverter-defibrillator; Older patients; Ventricular tachyarrhythmias; Wearable cardioverter-defibrillator; ACUTELY TERMINATING EPISODES; HIGH-RISK; VENTRICULAR-FIBRILLATION; ATRIAL-FIBRILLATION; CLINICAL-EFFICACY; DYSFUNCTION; INFARCTION; THERAPY; SHOCKS;
D O I
10.1016/j.hrthm.2018.04.014
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND Use of the wearable cardioverter-defibrillator (WCD) in older patients has not been described previously. OBJECTIVE The purpose of this study was to assess WCD wear time, risk of arrhythmic events during WCD use, and implantable cardioverter-defibrillator (ICD) implantation rates after the end of WCD use in patients with age >= 65 years vs <65 years. METHODS We stratified 1732 patients with ischemic and nonischemic cardiomyopathy from the Prospective Registry of Patients Using the Wearable Defibrillator Registry into 2 subgroups by age: those with age >= 65 years and those with age <65 years. Wear time, arrhythmic events, and end-of-use decisions, specifically ICD implantation or improvement in ejection fraction, were evaluated for each age group. RESULTS There were 722 patients with age >= 65 years (41.7%) and 1010 patients with age <65 years (58.3%). Daily WCD wear time was longer in the older population (median 22.8 h/d (IQR 21.5 23.2) vs 22.3 h/d (IQR 19.5- 23.0); P <.001). Patients with age >= 65 years experienced higher event rates, per 100 patient-years, for any sustained ventricular tachycardia/ventricular fibrillation (31.95 vs 9.82; P =.027) and ventricular tachycardia/ventricular fibrillation treated with WCD shock (6.92 vs 2.37; P =.034), particularly with ischemic cardiomyopathy. Younger patients experienced a trend toward a higher event rate for atrial arrhythmias with nonischemic cardiomyopathy (150.07 vs 74.86; P =.055). At the end of WCD use, ICD implantation was more frequent in older patients (41.8% vs 36.5%; P =.034). CONCLUSION Older patients had good compliance with the WCD, presented with more frequent ventricular arrhythmias, and were more likely to receive an ICD at the end of WCD use. The WCD may play a role in risk stratification of the older population.
引用
收藏
页码:1379 / 1386
页数:8
相关论文
共 50 条
  • [1] The US Experience of the Wearable Cardioverter-Defibrillator in Pediatric Patients
    Spar, David S.
    Bianco, Nicole R.
    Knilans, Timothy K.
    Czosek, Richard J.
    Anderson, Jeffrey B.
    CIRCULATION-ARRHYTHMIA AND ELECTROPHYSIOLOGY, 2018, 11 (07)
  • [2] Use of the wearable cardioverter-defibrillator - the Swiss experience
    Boldizsar, Kovacs
    Sven, Reek
    Christian, Sticherling
    Beat, Schaer
    Andre, Linka
    Peter, Ammann
    Roman, Brenner
    Nazmi, Krasniqi
    Andreas, Muller S.
    Omer, Dzemali
    Richard, Kobza
    Christian, Grebmer
    Laurent, Haegeli
    Jan, Berg
    Kurt, Mayer
    Jurg, Schlapfer
    Giulia, Domenichini
    Tobias, Reichlin
    Laurent, Roten
    Haran, Burri
    Urs, Eriksson
    Ardan, Saguner Ma
    Jan, Steffel
    Firat, Duru
    SWISS MEDICAL WEEKLY, 2020, 150 : w20343
  • [3] The wearable cardioverter-defibrillator in a real-world clinical setting: experience in 102 consecutive patients
    Erath, Julia W.
    Vamos, Mate
    Sirat, Abdul Sami
    Hohnloser, Stefan H.
    CLINICAL RESEARCH IN CARDIOLOGY, 2017, 106 (04) : 300 - 306
  • [4] The wearable cardioverter-defibrillator: current technology and evolving indications
    Reek, Sven
    Burri, Haran
    Roberts, Paul R.
    Perings, Christian
    Epstein, Andrew E.
    Klein, Helmut U.
    EUROPACE, 2017, 19 (03): : 335 - 345
  • [5] The wearable cardioverter-defibrillator vest: Indications and ongoing questions
    Sandhu, Uday
    Rajyaguru, Chirag
    Cheung, Christopher C.
    Morin, Daniel P.
    Lee, Byron K.
    PROGRESS IN CARDIOVASCULAR DISEASES, 2019, 62 (03) : 256 - 264
  • [6] Real life experience with the wearable cardioverter-defibrillator in an international multicenter Registry
    El-Battrawy, Ibrahim
    Kovacs, Boldizsar
    Dreher, Tobias C.
    Klein, Norbert
    Rosenkaimer, Stephanie
    Roger, Susanne
    Kuschyk, Jurgen
    Saguner, Ardan Muammer
    Kowitz, Jacqueline
    Erath, Julia W.
    Duru, Firat
    Akin, Ibrahim
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [7] Wearable cardioverter-defibrillator for prevention of sudden cardiac death after infected implantable cardioverter-defibrillator removal: A cost-effectiveness evaluation
    Healy, Christopher A.
    Carrillo, Roger G.
    HEART RHYTHM, 2015, 12 (07) : 1565 - 1573
  • [8] Risk stratification for implantable cardioverter defibrillator therapy: the role of the wearable cardioverter-defibrillator
    Klein, Helmut U.
    Goldenberg, Ilan
    Moss, Arthur J.
    EUROPEAN HEART JOURNAL, 2013, 34 (29) : 2230 - 2242
  • [9] Patients with a wearable cardioverter-defibrillator (WCD) Prescription, function and rehabilitation support
    Schlitt, A.
    Guha, M.
    Noutsias, M.
    Klein, H. H.
    Klein, H. U.
    HERZ, 2019, 44 (05) : 379 - 389
  • [10] Experience With the Wearable Cardioverter-Defibrillator in Patients at High Risk for Sudden Cardiac Death
    Waessnig, Nadine K.
    Guenther, Michael
    Quick, Silvio
    Pfluecke, Christian
    Rottstaedt, Fabian
    Szymkiewicz, Steven J.
    Ringquist, Steven
    Strasser, Ruth H.
    Speiser, Uwe
    CIRCULATION, 2016, 134 (09) : 635 - 643